OncoDNA

Executive Summary

OncoDNA is a Belgian precision medicine company founded in 2012 that provides comprehensive genomic profiling solutions for oncology. The company offers next-generation sequencing (NGS) kits for both solid and liquid biopsies, along with clinical interpretation software to guide cancer treatment decisions. By targeting healthcare providers, laboratories, and pharmaceutical companies, OncoDNA aims to democratize access to precision oncology. Its solutions enable tumor profiling from tissue and blood samples, supporting therapy selection and clinical trial matching. The company operates in the rapidly growing precision diagnostics market, driven by increased adoption of NGS and liquid biopsy. OncoDNA differentiates itself through integrated workflows that combine wet-lab kits with bioinformatics interpretation, reducing turnaround time and complexity for clinical labs. While privately held and lacking disclosed financials, the company's focus on translational genomics and partnerships with pharma positions it well in the competitive landscape. Key challenges include market penetration against larger players and reimbursement hurdles for comprehensive genomic testing.

Upcoming Catalysts (preview)

• Q2 2026Receipt of CE-IVD marking for a new liquid biopsy panel70% success
• H2 2026Announcement of a strategic partnership with a major pharmaceutical company for companion diagnostics55% success
• Q4 2026Series B or C funding round closure to support international expansion60% success